The FDA has approved Voranigo to treat certain patients with grade 2 astrocytoma or oligodendroglioma with select mutations, following surgery. The Food and Drug Administration (FDA) has approved ...

IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront treatment. By adding a newer, targeted therapy aimed at the underlying IDH ...

Brain tumors cannot always be successfully treated with conventional therapies. A team from Empa and the hospital network HOCH Health Ostschweiz is therefore developing nanozymes that can attack ...

Suggested remit: To appraise the clinical and cost effectiveness of vorasidenib within its marketing authorisation for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after ...

Q: Who should I consult when I have symptoms like memory loss, headaches and seizures? A: These symptoms can be seen in many disorders that affect the brain, hence you should first consult your ...

MicroRNAs as specific biomarkers for distinguishing between primary and metastatic brain tumors ...

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin ...

Pilocytic astrocytoma is one of the most common central nervous system glial neoplasms seen in the pediatric population. These tumors occur most frequently in patients between the ages of 0 and 14 ...

The recent report of an astrocytoma following the pyramidal tract (Dec. 7 issue) 1 was quite interesting. We report on the use of fludeoxyglucose F18 positron-emission tomography (PET) in the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved vorasidenib for certain patients with astrocytoma or oligodendroglioma. The indication applies ...